[CAS NO. 2750001-23-9]  AZD0095

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2750001-23-9]

Catalog
HY-148517
Brand
MCE
CAS
2750001-23-9

DESCRIPTION [2750001-23-9]

Overview

MDL-
Molecular Weight500.60
Molecular FormulaC27H32N8O2
SMILESCC1=C(O[C@H]2CN(C3=CC=C(C4=NN=C(CN5CCOCC5)C=C4)C=C3)CC2)C(C)=NC6=NC(C)=NN16

For research use only. We do not sell to patients.

Summary

AZD0095 is a selective and orally active MCT4 inhibitor ( IC 50 : 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib (HY-10205) [1] .


IC50 & Target

MCT4

1.3 nM (IC 50 )


In Vitro

AZD0095 (0-50 µM) inhibits cell proliferation in NCI-H358 cells (high expression of MCT4), with an IC 50 of 26 nM [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

AZD0095 (100 mg/kg, p.o. bid) together with Cediranib (3 mg/kg, p.o.) reduces tumor growth in a murine NCI-H358 xenograft [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Murine NCI-H358 xenograft [1]
Dosage: 100 mg/kg together with Cediranib (3 mg/kg)
Administration: Oral administration (p.o.)
Result: Reduced tumor growth more efficiently than AZD0095 or AZD2171 alone.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month